CAPA Plans: Solutions, not Blame

Similar documents
SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS

Reporting an Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) to the IRB

Yale University Human Research Protection Program

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH

Issue in IRB Approvals:

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Post-Approval Submissions

The IRB is Your Friend. David W. Kaufman, Sc.D. Chair, Panel Orange

What s New in GCP? FDA, OHRP Issue Harmonized Guidance on Transferring IRB Oversight of Clinical Studies

Study Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB)

1. Review and approval of the consent document is a responsibility that FDA assigns to the IRB with jurisdiction

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

EMERGENCY USE 03/02/2016

SOP 801: Investigator Qualifications and Responsibilities

Screening and Enrollment Log. List of all subjects screened and all subjects screened and enrolled in the study.

7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL

NONCOMPLIANCE. 1. Overview

Independent Ethics Committees

Section 8. Continuing Review of Ongoing IRB-Approved Research (Revised 7/1/10)

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Penn as Central IRB FAQ

University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP)

IOWA STATE UNIVERSITY Institutional Review Board. Policy on IRB Review of Protocol Deviations and Noncompliance for Non-exempt Research

Inspections, Compliance, Enforcement, and Criminal Investigations

PRINCIPAL INVESTIGATOR S ACKNOWLEDGMENT OF RESPONSIBILITIES

Wayne State University Institutional Review Board

RESEARCH PROTECTIONS OFFICE

AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016

Humanitarian Use Devices Made Simple

Chapter 4 Institutional Review Board (IRB) Roles and Authorities

Human Research Protection Program Policy

Supersedes Document Dated: 7/7/11. SOP: RR 401 Version No.: 07 Version Date: 9/8/15 EXPEDITED REVIEW 1. POLICY

Effective Date: January 16, 2012 Policy Number: MHC_RP0107. Revised Date: November 2, 2015 Oversight Level: Corporate

Human Research Protections Program Medical College of Wisconsin and Froedtert Memorial Lutheran Hospital

DEPARTMENT OF HEALTH & HUMAN S E RVICES, 'mgr,':~~ MAY WARNING LETTE R

CONTINUING REVIEW CRITERIA FOR RENEWAL

Illinois Institute of Technology Institutional Review Board Handbook of Procedures for the Protection of Human Research Subjects

University of Wisconsin Colleges Administrative Policy #56 NON-COMPLIANCE IN HUMAN SUBJECTS RESEARCH

Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013; 05/01/2016; 10/16/2018

Date Effective 4/21/2008 Identification

Current Status: Active PolicyStat ID: Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021

Administrative Hold, Suspension, or Termination of IRB Approval

POLICY NO EXEMPT RESEARCH... 4 POLICY NO DISCLOSURE OF RESEARCH LAB TEST RESULTS... 5

CONTINUING REVIEW CRITERIA FOR RENEWAL

(y9. &i?r, JUL t Certified-Return Receipt Requested WARNING LE7TER

Institutional Review Board Standard Operating Procedure. Suspension and Termination of IRB Approval

OHRP Guidance on Written IRB Procedures

HUD and HDE Topics. Humanitarian Use Device and. Humanitarian Use Device. Humanitarian Device Exemption

Institutional Review Board - Restriction s Impo sed

Effective Date Revisions Date Review by the Convened Institutional Review Board

Investigator Manual. If you have questions about whether an activity requires IRB review, contact the IRB Office.

EXPEDITED REVIEW. Terms used in this policy, but not defined herein shall have the meanings set forth in the Glossary.

INSTITUTIONAL REVIEW BOARD (IRB) PROCEDURES

CONTINUING REVIEW 3/7/2016

SOP 903: HRPP AND NON-COMPLIANCE

SUSPENSION OR TERMINATION OF HUMAN SUBJECTS RESEARCH

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH

Initial Review. Approved By: Michele Kennett, JD, MSN, LLM Associate Vice Chancellor for Research. Table of Contents

Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval

SOP 5.06 Full Committee Review: Initial IRB Review

Baptist Health Institutional Review Board. Study Closure Report (Expedited Review) IRB #: Study Title:

SOP Title Review of Research: Devices for Humanitarian Uses

University of Cincinnati. Radiation Safety Committee Operations Guidelines Statement of Policy (RSC Guidelines) RSC Guidelines (revision 5)

UNIVERSITY OF GEORGIA Institutional Review Board

4 Staff Selection, Appraisal and Development. To prevent harm by identifying and controlling potential hazards.

CONTINUING REVIEW OF APPROVED IRB PROTOCOLS

IRB Training October 22, 2015

IRB COMPOSITION AND IRB MEMBER ROLES AND RESPONSIBILITIES

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES

HEALTH CARE SYSTEMS RESEARCH NETWORK

INSTITUTIONAL REVIEW BOARD MANUAL: PURPOSE and POLICIES.

PIQCS HACCP Minimum Certification Standards

Review of Research by the Convened IRB

English. wada-ama.org

SITE NAME: ISF DOCUMENT VERSION CHECKLIST Complete yes or no to confirm the presence or absence of each document specified.

21 CFR Part 56 - Institutional Review Boards

Michigan State University Human Research Protection Program

Human Subjects in Research Review and Monitoring Form. Not applicable

Lapse in IRB Approval

JUN L WARNING LETTER VIA FEDERAL EXPRESS

Jeffrey A. Cooper, MD, MMM Huron Consulting Group

Version 1. Submission Guide and Policies

CUNY HRPP Policy: Suspension or Termination of Human Subject Research

To assure knowledge and compliance by documenting the continuing review procedure of approved projects for the IRB.

RESEARCH SUBMISSION REQUIREMENTS

SOP #2-2 Version #1 Date First Effective: December 14, Page 1 of 6

Food and Drug Administration Center for Devices an d * 1Ya I a Radiological Health WARNING LETTE R

Florida State University IRB Standard Operational Procedures

Ceded IRB Review. The project involves prisoners or other vulnerable populations that require special considerations.

HSPP Standard Operating Procedures

COMPLIANCE MONITORING

Procedure Department: HUMAN RESEARCH PROTECTIONS PROGRAM Policy Number: II.B.1

I. Summary. II. Responsibilities

Standard Operating Policy and Procedures (SOPP) 3:

To assure knowledge and compliance by documenting the annual administrative review and continuing IRB review of non-exempt projects for the IRB.

Arkansas Tech University Institutional Review Board

Info Sheet - Operations Office for Human Research Studies

Alternate Suction to Reduce Prolonged Air Leak

IV. Basic Procedures for Human Research Protections

Institutional Review Board Responsibilities in making the Significant Risk and Non-significant Risk Device Determination

Central IRBs: Where Does the UR Fit into the Picture?? Kelley O Donoghue Tiffany Gommel Emily Flagg April 15 th 2015

Hazard Identification

Transcription:

CAPA Plans: Solutions, not Blame Lorrie D. Divers, CCRP, RQAP-GCP Executive Director, Global Quality Assurance & Compliance ACM Medical Laboratory / ACM Global Central Laboratory Clinical Translation Science Institute, University of Rochester February 25, 2014 Rochester NY

Disclaimers The contents of this presentation are my own and do not represent the opinions or advice of my current employer, ACM Medical Laboratory. The information regarding FDA inspections contained in this presentation was obtained from publicly available sources. My interpretation of this information is also my own. 25-Feb-2014 Divers, CTSI URMC 2

Objectives What is the purpose of a CAPA plan? Who should develop the CAPA? Why does conducting effective root cause analysis matter? How, what, where, when and why matter more than who Applying the concepts and techniques to actual audit findings Audience participation! 25-Feb-2014 Divers, CTSI URMC 3

Corrective and Preventive Action Plans Something happens that Is harmful or potentially harmful Isn t supposed to happen at all Doesn t happen the way it is supposed to Is unexpected Causes other problems We don t want happening again 25-Feb-2014 Divers, CTSI URMC 4

Something happens. 1. Stop for my coffee 2. Come out of coffee shop to find a large dent in my car door. 25-Feb-2014 Divers, CTSI URMC 5

Purpose of CAPA Corrective Actions = Reactive Actions Correct the immediate problem It s morning, I haven t had my coffee yet. Determine what caused the problem Again, it s morning. Eliminate (correct) the source of the problem so that it does not happen again Hey, just don t get out of bed! 25-Feb-2014 Divers, CTSI URMC 6

Purpose of CAPA Preventive Actions = Proactive Actions Ensure the Cause and the problem does not happen again On windy mornings. Block the cause (or potential causes) Use the drive through. Avoid the problem (or problems like it) No more dents and dings (and no more ill temper) 25-Feb-2014 Divers, CTSI URMC 7

Purpose of CAPA The some things that can happen in clinical research are far more serious Harm to the current study subject Harm to future study subjects Inaccurate, incomplete, unreliable data Drug, medical device, biologic may be approved (or approval may be denied) inappropriately Harm to future patients 25-Feb-2014 Divers, CTSI URMC 8

Who develops the CAPA? Why can t they just tell us what to do and exactly how to do it? How does because they said so thinking make you feel? Clinical investigator responsibility Guidance for Industry: Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects (October, 2009) Practical, circumstantial expertise One solution does not correct or prevent every problem 25-Feb-2014 Divers, CTSI URMC 9

Why root cause analysis? Back to the coffee shop.. What if I had just gotten in my car, swearing at morning, swearing at jerks in parking lots, wishing I d never gotten out of bed? 25-Feb-2014 Divers, CTSI URMC 10

Why root cause analysis? To fix the problem effectively. it s important to understand what the problem is 25-Feb-2014 Divers, CTSI URMC 11

Why root cause analysis? Tylenol for knee pain (immediate correction) but what about the underlying cause (root cause) if that pain is frequent and effects mobility? Wouldn t you want to eliminate that cause and avoid possibly falling or requiring surgery? 25-Feb-2014 Divers, CTSI URMC 12

Analyze this. Audit Finding: The Drug Dispensing/Compliance Log (Form 16) for Visits 1, 3, and 4 do not include documentation of the Bottle Identification Number that was dispensed. CAPA Plan: We will be careful to avoid repeating these mistakes. 25-Feb-2014 Divers, CTSI URMC 13

The human factor Human error is probably the number one CAPA response auditors receive Obviously.. We are all human! We all make mistakes (even auditors do!) But why? Important to understand why who s to blame? 25-Feb-2014 Divers, CTSI URMC 14

Root Cause Analysis The 5 whys of a problem Why tends to make people ask who before they ask more important questions Remember, the purpose of a CAPA is to Correct, determine cause and eliminate the problem Ensure the cause is blocked and similar problems avoided 25-Feb-2014 Divers, CTSI URMC 15

Root Cause Analysis The 5 Ws (and be specific) instead What happened? Where did it happen? When did it happen? Who was involved? Weight (impact) of the problem? 25-Feb-2014 Divers, CTSI URMC 16

Our Earlier Audit Finding The Drug Dispensing/Compliance Log (Form 16) for Visits 1, 3, and 4 do not include documentation of the Bottle Identification Number that was dispensed. 25-Feb-2014 Divers, CTSI URMC 17

Incomplete drug dispensing log What exactly happened? A drug dispensing log was not completed for three visits 3 out of how many visits? Is the log required per the protocol or study procedures? Yes What is the purpose of the log? To track specifically which bottles of drug by number were dispensed to which patient and at what visits Why is that important? 25-Feb-2014 Divers, CTSI URMC 18

Incomplete drug dispensing log Where did this occur? Is the log completed where study subjects are seen (and where are they seen)? Or. Are study subjects seen in the clinic but the log is filled out later in an office? When did it occur? 3 visits (1, 3, and 4) out of 5 What was different about these visits? Study coordinator did not go straight from clinic to study office 25-Feb-2014 Divers, CTSI URMC 19

Incomplete drug dispensing log Who was involved? Study coordinator Clinical investigator - Did not review and sign dispensing log Impact (weight) of this problem How many study subjects are enrolled in this study? How many visits was this a problem at? One subject enrolled, 3 out of 5 visits versus Ten subjects enrolled, 3 our of 5 visits for just this one subject 25-Feb-2014 Divers, CTSI URMC 20

Root causes Investigator and study coordinator unaware of purpose of Drug Dispensing Log Log kept in office but study subjects seen in clinic Impact: Happened on first (and only) enrolled subject Hmmmm?... 25-Feb-2014 Divers, CTSI URMC 21

Our Earlier CAPA We will be careful to avoid repeating these mistakes. What might the CAPA be now that the causes are understood? To correct the immediate problem (bottle identification numbers not logged), what might be done? To eliminate the source (causes) of the problem, what might be done? To prevent the causes (and similar problems) from reoccurring, what could be done? 25-Feb-2014 Divers, CTSI URMC 22

Frequency and Impact Two important factors to consider in a root cause analysis and to assist with developing effective CAPA are Frequency of the problem The impact (or potential impact) of the problem 25-Feb-2014 Divers, CTSI URMC 23

Frequency and Impact Why is this important to root cause analysis and to effective CAPA? Back to human error.. If a study related form is filled out wrong once or twice, or only filled out wrong by one person, is that different than a form being filled out wrong repeatedly or filled out wrong by numerous people? Does an effective CAPA depend on the answer to these questions? 25-Feb-2014 Divers, CTSI URMC 24

Frequency and Impact 1) What if someone in the US records the date as 25/2/14, what is the impact? 2) What if they record the date as 3/5/14 but it is a global study, is that different? Is an effective CAPA different for 1) than it is for 2)? One way to help evaluate the difference is to assess the risk 25-Feb-2014 Divers, CTSI URMC 25

Frequency and Impact = Risk IMPACT (Severity) Negligible Minor Major Critical Frequency Continual 5 Frequent 3 Occasional 2 1 3 5 10 Rare 1 Note that Impact is weighted, as it should be relative to subjects rights, safety and welfare Source: http://mastercontrolinc.blogspot.com/2014/02/3-loops-in-1-as-reflected-infda.html?source=n3w5pharma 25-Feb-2014 Divers, CTSI URMC 26

Frequency and Impact = Risl * 25/2/14 US Only Study * Fairly obvious what the correct date is, right? Assume it happens occasionally for a study visit # 3/5/14 Global Study # Could be March 5 th, could be May 3 rd Problematic anytime the month and/or day are < 12? IMPACT (Severity) Negligible Minor Major Critical Frequency Continual 5 1 3 5 10 Frequent 3 # # # # # Occasional 2 ********** 25-Feb-2014 Divers, CTSI URMC 27 Rare 1

Frequency and Impact = Risk FDA Warning letter issued 19 Nov 2013 to Sreedhar Samudrala Two clinical trials of an inhaled medication for moderate COPD in patients with cardiovascular disease Failed to ensure that the investigation was conducted according to the investigational plan [protocol] per 21 CFR 312.60 25-Feb-2014 Divers, CTSI URMC 28

FDA Warning Letter, 11/19/13 Protocol #1 required a FEV 1 /FVC ratio of < 0.70 at screening 11/31 subjects did not meet this criteria Protocol #2 required FEV 1 > 50% and < 70% of predicted normal values calculated using NHANES III reference equations at screening 4/31 subjects did not meet this criteria (3 above, one below the requirement) 25-Feb-2014 Divers, CTSI URMC 29

FDA Warning Letter, 11/19/13 Also, in protocol #2, one subject did not meet the age criteria for enrollment and one subject was not being treated for any of the cardiovascular conditions required for enrollment per protocol How would you assess the frequency and impact of these inspection (audit) observations? 25-Feb-2014 Divers, CTSI URMC 30

Frequency and Impact = Risk IMPACT (Severity) Negligible Minor Major Critical Frequency Continual 5 Frequent 3 Occasional 2 1 3 5 10 Rare 1 25-Feb-2014 Divers, CTSI URMC 31

FDA Warning Letter, 11/19/13 Dr. Samudrala s written response stated, Investigators are required to sign a document prior to randomization that states [whether] Inclusion/Exclusion Criteria have been met. All investigators and study staff personnel were reeducated. A new spirometer was purchased to replace the spirometer that was inadequate for the study. 25-Feb-2014 Divers, CTSI URMC 32

FDA Warning Letter, 11/19/13 Not surprisingly, the FDA stated, Your response is inadequate because it is insufficiently detailed with respect to your corrective action plan. You have not provided details regarding the document that investigators are required to sign, and you have not submitted a copy of that document. You also have not provided details or documentation regarding the reeducation that took place. Without this information, we cannot assess whether these corrective actions are adequate to prevent further ocurrences of this type of violation. 25-Feb-2014 Divers, CTSI URMC 33

FDA Warning Letter, 11/19/13 Do you think a root cause analysis was done? Do you think signing a document will correct and prevent re-occurrence? And who said anything about an inadequate spirometer?? 25-Feb-2014 Divers, CTSI URMC 34

Effective CAPA Require Facts Facts are necessary and critical for effective problem solving Ask the people involved Go to the location where the error occurred Look at the documents It s about what happened, how and why it happened, not who s to blame 25-Feb-2014 Divers, CTSI URMC 35

Laboratory aide cuts herself with a pathology knife. She must need re-training. Asking the 5 whys revealed: The knife was left by the sink; the area was not cleared from the previous day; clearing is not a habit; there is no procedure for how/when to clear the cleaning area Interviewing her to assess What, Where, When it happened revealed. History of intimidation by physicians in her previous department so she didn t want to move it Weight (impact): She needed 15 stitches! Looking at the knife. Revealed the cutting edge was not readily apparent Source: Techniques for Root Cause Analysis, Patricia M Williams, BUMC Proceedings 200l;14:154-157 25-Feb-2014 Divers, CTSI URMC 36

Effective CAPA How do you know you have the right root cause? Go back to all your Ws and see if the causes you identified explain the problem if.. Root causes of incomplete drug dispensing log were determined to be: Locational (needed to be in the clinic) Vocational (PI and study coordinator did not understand purpose) Procedural (PI was not required to sign a protocol required form) 25-Feb-2014 Divers, CTSI URMC 37

Effective CAPA Be SMART Specific, Measurable, Attainable, Relevant, Time-bound/Trackable Describe not just what you re going to do but how, by when and by whom For high risk problems, strongly advisable to include a plan to check at a later date to ensure your CAPA was effective Plan to fail. 25-Feb-2014 Divers, CTSI URMC 38

Let s Look at an Audit Finding Together The protocol states, If a non-anemic subject becomes anemic during the study, this will constitute a condition which precludes further participation in the study, and the subject will be paid for participation to date. Anemia is defined as hemoglobin below the lower limit of normal. The following three subjects are documented as becoming anemic during the study in the protocol deviation log but were not withdrawn in accordance with the protocol. 25-Feb-2014 Divers, CTSI URMC 39

Let s Look at an Audit Finding Together a. Subject 001: Labs were suspended when the subject was found to be anemic at Visit 2. The subject s PCP re-ordered labs with a result of 35. Blood draws were then resumed. b. Subject 007: This subject was found to be anemic based on the blood draws completed at Visit 12. Blood draws were initially suspended and then resumed at Visit 16, which with the subject remained anemic. Further blood draw were discontinued. c. Subject 010: This subject was found to be anemic based on blood draws completed at Visit 4. Blood draws were discontinued until the subject was assessed further. [No follow-up on this case documented in the protocol deviation log]. 25-Feb-2014 Divers, CTSI URMC 40

Let s Look at the Investigator s Response Investigator s response: Because participation in the trial yields many data points in addition to the labs, these subjects were not discontinued as their input was still of value to the study. These instances, and any others that occur, will be listed as protocol deviations and reported to the RSRB. Regarding Subject 010 who was anemic, a follow up will be conducted on this subject, and reported to the RSRB under separate cover. 25-Feb-2014 Divers, CTSI URMC 41

I need a note taker to volunteer. How would your 5 Ws proceed? What happened? Be specific.be more specific.keep going Where? When? Who was involved? Oooops, missing a W 25-Feb-2014 Divers, CTSI URMC 42

Let s Look at an Audit Finding Together Weight (impact)? Let s assume the frequency was 3/10 subjects But what about that statement in the Investigator s response: These instances, and any others that occur.? Let s assume it is a investigational drug to treat ulcerative colitis. How would you assess impact of not withdrawing non-anemic subjects that develop anemia while on study? Is your risk assessment different if it is an investigational drug for knee pain? 25-Feb-2014 Divers, CTSI URMC 43

Frequency and Impact = Risk IMPACT (Severity) Negligible Minor Major Critical Frequency Continual 5 Frequent 3 Occasional 2 1 3 5 10 Rare 1 25-Feb-2014 Divers, CTSI URMC 44

Let s work on the CAPA together Corrective Actions = Reactive Actions Correct the immediate problem What might that be? Determine what caused the problem Your 5 Ws Eliminate (correct) the source of the problem so that it does not happen again What are your proposed corrective action(s)? 25-Feb-2014 Divers, CTSI URMC 45

Purpose of CAPA Preventive Actions = Proactive Actions Note: These may, or may not be the same as some your corrective actions Ensure the Cause and the problem does not happen again Would checking effectiveness at a later date be appropriate for this situation? Block the cause (or potential causes) Avoid the problem (or problems like it) 25-Feb-2014 Divers, CTSI URMC 46

To Summarize. Problems in clinical research such as noncompliance with the protocol, Investigator s Brochure, regulations, IRB approval, study procedures or your own procedures Creates risk for current and future study subjects May impact approval (pro or con) for drugs, medical devices, biologics Creates potential risk for future patients who may (or may not be able to) receive the treatments we re researching today 25-Feb-2014 Divers, CTSI URMC 47

To Summarize. Audits help to identify problems (or potential problems) Protect research subjects rights, safety and welfare Educational for study staff Educational for the IRB Effective CAPA correct and prevent such problems Really understanding the facts and identifying the cause(s) is critical It s about solutions, not blame! 25-Feb-2014 Divers, CTSI URMC 48

Questions? 25-Feb-2014 Divers, CTSI URMC 49

Contact Information Lorrie D. Divers, CCRP, RQAP-GCP 585-429-2386 LDivers@acmgloballab.com It takes less time to do a thing right than to explain why you did it wrong. Henry Wadsworth Longfellow 25-Feb-2014 Divers, CTSI URMC 50